Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease. (13th July 2020)

• Record Type: Journal Article
• Authors: Lim, Bryant; Fowler, Christopher; Li, Qiao-Xin; Rowe, Christopher; Dhiman, Kunal; Gupta, Veer Bala; Masters, Colin L.; Doecke, James D.; Martins, Ralph N.; Collins, Steven; Diamandis, Eleftherios P.
• Is Part Of: Neuroscience letters. Volume 731(2020)
• Publication Date: 2020-07-13
• Subjects: Alzheimer's disease -- Cerebrospinal fluid -- Neuronal pentraxin receptor -- Positron emission tomography -- Aβ-amyloid -- Neurofilament light; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2020.135078
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Neuronal pentraxin receptor (NPTXR) is a preclinical AD biomarker. CSF NPTXR levels differs in PET-amyloid positive and negative individuals. CSF NPTXR strongly associated with AD CSF biomarkers, β-amyloid and tau species. CSF neurofilament light is not informative in preclinical AD. Abstract: Multifactorial pathological processes of Alzheimer's disease (AD) begin decades prior to clinical onset. Early identification of patients at risk of developing AD using biomarkers reflecting various aspects of pathogenesis is necessary for prevention and early intervention. Cortical β-amyloid (Aβ) burden assessed by positron emission tomography (PET) or cerebrospinal fluid (CSF) levels of Aβ42 are validated biomarkers for early identification. Recently, alterations in levels of neuronal proteins, neuronal pentraxin receptor (NPTXR) and neurofilament light (NfL), in the CSF have emerged as promising AD biomarkers. However, their association with Aβ deposition is not well understood. In this pilot study, we evaluate whether CSF NfL and NPTXR are associated with PET-Aβ imaging and core CSF biomarkers (Aβ42, T-tau, and P-tau). CSF samples were collected from a sub-cohort of participants from the Australian Imaging Biomarkers and Lifestyle study of aging (AIBL) and categorized as either PET-Aβ positive (n = 15) or negative (n = 15). NPTXR was significantly lower in PET-Aβ positive than negative individuals ( p = 0.04), and correlated with Aβ42 (rho = 0.69, p < 0.0001), T-tau (rho = 0.45, p = 0.01), and P-tau (rho = 0.51, p = 0.004). However, CSF NfL was not significantly different between PET-Aβ positive and negative individuals and did not correlate with any of the core CSF biomarkers. Similar associations of NPTXR and the core CSF biomarkers persisted in the cognitively normal individuals. Together, NPTXR concentration in CSF may be more sensitive NfL to identify AD risk during the preclinical stage, warranting further investigation into its contribution to AD pathogenesis.